Literature DB >> 26801979

Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.

Silvia Boero¹, Anna Morabito², Barbara Banelli³, Barbara Cardinali⁴, Beatrice Dozin⁵, Gianluigi Lunardi⁶, Patrizia Piccioli⁷, Sonia Lastraioli⁸, Roberta Carosio⁹, Sandra Salvi¹⁰, Alessia Levaggi¹¹, Francesca Poggio¹², Alessia D'Alonzo¹³, Massimo Romani¹⁴, Lucia Del Mastro¹⁵, Alessandro Poggi¹⁶, Maria Pia Pistillo¹⁷.

Abstract

Entities: Chemical Disease Gene Mutation Species

Year: 2016 PMID： 26801979 PMCID： PMC4724068 DOI： 10.1186/s12967-016-0779-y

Source DB: PubMed Journal: J Transl Med ISSN： 1479-5876 Impact factor: 5.531

× No keyword cloud information.

Erratum to: J Transl Med (2015) 13:324 DOI 10.1186/s12967-015-0680-0

It has come the publisher’s attention that the original version of this article [1] unfortunately contained an error. In Table 3, first column, the FcγRIIA 131 H>R genotypes were incorrectly labelled. In particular, V/V should have read H/H, V/F should have read H/R and F/F should have read R/R. Please note that this correction does not change the genotype numerical values of FcγRIIA polymorphism. The correct Table 3 has been published as Table 1 in this Erratum.

Table 1

Genotypic and allelic frequencies of FcγRIIIA and FcγRIIA polymorphisms in breast cancer patients and healthy controls

Genotypes	n (%)			P ^*	Alleles	n (frequency)			P°
Genotypes	NEO (n = 15)	MTS (n = 10)	CTR (n = 33)	P ^*	Alleles	NEO (2n = 30)	MTS (2n = 20)	CTR (2n = 66)	P°
FcγRIIIA 158V>F					FcγRIIIA 158V>F
V/V	4 (26.7)	3 (30.0)	6 (18.2)	0.741	V	13 (0.43)	8 (0.40)	26 (0.39)	0.934
V/F	5 (33.3)	2 (20.0)	14 (42.4)		F	17 (0.57)	12 (0.60)	40 (0.60)
F/F	6 (40.0)	5 (50.0)	13 (39.4)
HWE	P = 0.213	P = 0.065	P = 0.522
FcγRIIA 131H>R					FcγRIIA 131H>R
H/H	3 (20.0)	4 (40.0)	9 (27.3)	0.499	H	14 (0.47)	10 (0.50)	35 (0.53)	0.843
H/R	8 (53.3)	2 (20.0)	17 (51.5)		R	16 (0.53)	10 (0.50)	31 (0.47)
R/R	4 (26.7)	4 (40.0)	7 (21.2)
HWE	P = 0.782	P = 0.058	P = 0.845

Genotyping of FcγRIIIA 158V>F was performed by a newly developed PSQ method after pre-amplification of FcγRIIIA gene. Genotyping of FcγRIIA 131H>R was performed by T-ARMS PCR and SBT. Conventionally, the 158V>F variant corresponds to the G>T SNP [i.e. guanine corresponding to valine (V) and thymine corresponding to phenylalanine (F)] and the 131H>R SNP corresponds to the A>G SNP [i.e. adenine corresponding to histidine (H) and guanine corresponding to arginine (R)]

Comparison of FcγR genotypic and allelic frequencies between patients and control subjects was estimated using the Pearson’s χ2 test (P* value) and the Fisher’s test (P° value), respectively. Statistical significance: P < 0.05

NEO neoadjuvant, MTS metastatic, CTR controls, HWE Hardy–Weinberg equilibrium. HWE was tested by the Pearson’s χ2 test (P < 0.05 indicates lack of HWE)

Genotypic and allelic frequencies of FcγRIIIA and FcγRIIA polymorphisms in breast cancer patients and healthy controls Genotyping of FcγRIIIA 158V>F was performed by a newly developed PSQ method after pre-amplification of FcγRIIIA gene. Genotyping of FcγRIIA 131H>R was performed by T-ARMS PCR and SBT. Conventionally, the 158V>F variant corresponds to the G>T SNP [i.e. guanine corresponding to valine (V) and thymine corresponding to phenylalanine (F)] and the 131H>R SNP corresponds to the A>G SNP [i.e. adenine corresponding to histidine (H) and guanine corresponding to arginine (R)] Comparison of FcγR genotypic and allelic frequencies between patients and control subjects was estimated using the Pearson’s χ2 test (P* value) and the Fisher’s test (P° value), respectively. Statistical significance: P < 0.05 NEO neoadjuvant, MTS metastatic, CTR controls, HWE Hardy–Weinberg equilibrium. HWE was tested by the Pearson’s χ2 test (P < 0.05 indicates lack of HWE)

1 in total

1. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.

Authors: Silvia Boero; Anna Morabito; Barbara Banelli; Barbara Cardinali; Beatrice Dozin; Gianluigi Lunardi; Patrizia Piccioli; Sonia Lastraioli; Roberta Carosio; Sandra Salvi; Alessia Levaggi; Francesca Poggio; Alessia D'Alonzo; Massimo Romani; Lucia Del Mastro; Alessandro Poggi; Maria Pia Pistillo
Journal: J Transl Med Date: 2015-10-08 Impact factor: 5.531

1 in total